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Serious knee pain and related disability have an annual prevalence of approximately 
25% on those over the age of 55 years. As curative treatments for the common knee 
problems are not available to date, knee pathologies typically progress and often lead 
to osteoarthritis (OA). While the roles that the meniscus plays in knee biomechanics are 
well characterized, biological mechanisms underlying meniscus pathophysiology and 
roles in knee pain and OA progression are not fully clear. Experimental treatments for 
knee disorders that are successful in animal models often produce unsatisfactory results 
in humans due to species differences or the inability to fully replicate disease progression 
in experimental animals. The use of animals with spontaneous knee pathologies, such 
as dogs, can significantly help addressing this issue. As microscopic and macroscopic 
anatomy of the canine and human menisci are similar, spontaneous meniscal pathologies 
in canine patients are thought to be highly relevant for translational medicine. However, 
it is not clear whether the biomolecular mechanisms of pain, degradation of extracellular 
matrix, and inflammatory responses are species dependent. The aims of this review are 
(1) to provide an overview of the anatomy, physiology, and pathology of the human and 
canine meniscus, (2) to compare the known signaling pathways involved in spontaneous 
meniscus pathology between both species, and (3) to assess the relevance of dogs with 
spontaneous meniscal pathology as a translational model. Understanding these mech-
anisms in human and canine meniscus can help to advance diagnostic and therapeutic 
strategies for painful knee disorders and improve clinical decision making.
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iNTRODUCTiON
The knee is one of the joints most commonly affected by osteoarthritis (OA), usually secondary to 
anterior cruciate ligament (ACL), meniscal injuries, trauma, or overuse (1). Approximately 25% of 
people over the age of 55 have suffered from a significant episode of knee pain in the past year of their 
life, with half of these people reporting associated disability (1). As curative treatments for these com-
mon knee problems are not available to date, the diseases typically progresses, often leading to OA 
and the associated chronic pain and disability. With aging of the population and increasing obesity, 
the prevalence and socioeconomic impact of painful knee pathologies are expected to rise (1, 2).
The knee joint is composed of the fibrous joint capsule, the synovial membrane, the joint cavity 
with synovial fluid (SF), menisci, ligaments, and bones lined with articular cartilage. The overall 
2Krupkova et al. The Pathobiology of the Meniscus
Frontiers in Veterinary Science | www.frontiersin.org April 2018 | Volume 5 | Article 73
function of the knee joint is to allow motion and provide stability 
for load transfer between femur and tibia. Anatomy and function 
of the knee undergo age-related changes caused by shifts in cell 
density and phenotypes and molecular, structural, and mechani-
cal alterations of the extracellular matrix (ECM), influencing 
the load distribution and joint kinematics. Damage to any of the 
knee structures can lead to loss of biological and biomechanical 
homeostasis and contribute to progressive degeneration of the 
whole joint. Despite the clinical importance of pain associated 
with degenerative joint disease, it is still unclear which structures 
of the knee are specifically painful and to what extent. While the 
meniscus plays a crucial role in biomechanics of the knee, its role 
in pain generation is not fully clear. Explaining the biological 
mechanisms underlying meniscus pathophysiology can therefore 
help to advance therapeutic strategies against progression of 
painful knee disorders.
Limitations to effective clinical application of translational 
joint research can be caused not only by species-related differ-
ences in metabolism, biology, and biomechanics but also by the 
inability to fully replicate the course of spontaneous pathol-
ogy in animals. Pre-existing pathophysiological mechanisms 
underlying progressive knee degeneration in aging humans are 
commonly not active in experimental animals (3), causing over-
estimation of therapeutic effects (3, 4). As an example, human 
knees often have been under the influence of altered mechanical 
loading, catabolism, and inflammation for a long time before 
becoming symptomatic. Therefore, it can be expected that the 
healing responses of the symptomatic human knee are dimin-
ished when compared with joints of experimental animals that 
are younger and/or treated at or near the time of insult. The use 
of animal models with spontaneous joint pathology can signifi-
cantly help address this limitation to effective translational joint 
research.
Both microscopic and macroscopic anatomy of the canine and 
human menisci are similar, however, biomolecular differences 
underlying meniscus pathologies in human and dog, have not 
yet been fully elucidated. Therefore, the aims of this review are (1) 
to provide an overview of the anatomy, physiology, and pathology 
of the human and canine meniscus, (2) to compare the known 
signaling pathways involved in spontaneous meniscus pathology 
between both species, and (3) to assess the relevance of dogs with 
spontaneous meniscal pathology as effective translational models 
for clinical application to human meniscal pathology.
HUMAN MeNiSCUS
Anatomy and Physiology
The medial and lateral menisci are semicircular fibrocartilages 
anchored to the tibia and femur by meniscal ligaments. Although 
the gross anatomy of human and canine menisci is similar, small 
differences can be found in the meniscal attachments to femur 
and tibia (5).
The contributions of the menisci to knee joint function include 
absorption and distribution of mechanical loads, congruity 
and stabilization, lubrication, nutrition, and mechano- and 
proprioception (6). The meniscal tissue is composed of water 
(±70%), collagens (±20%), glycosaminoglycans (GAG) (±1%), 
non-collagenous proteins (1%), and cells (7, 8). Collagen type I is 
a major component of the ECM, which is produced by the cells. 
Collagen type I is distributed throughout the whole meniscus, 
from the peripheral to inner area, organized in circumferential 
fibers to culminate in the anterior (cranial) and posterior (caudal) 
menisco-tibial ligaments (7, 9, 10). Collagen type II is found 
mainly in the inner avascular zone, where it shows an organized 
network of circumferential and radial fibers (7, 10). An organ-
ized network of proteoglycans (aggrecan, decorin, and biglycan) 
is also predominantly located in inner zone (7, 11). Adhesion 
glycoproteins such as fibronectin and thrombospondin connect 
cells with the surrounding ECM (8). No major differences in 
composition are found between human and canine meniscus (4).
Cells found in human and canine menisci are classified as 
chondrocytes and fibrochondrocytes, distributed according to 
the ECM they produce: chondrocyte-like cells are located in 
inner (avascular) part of the menisci, particularly in the ante-
rior and posterior horns, whereas fibrochondrocytes are found 
in the outer (vascular) layers (7, 8). Meniscal cells are involved 
in responses to mechanical loading, osmolarity, and pressure 
(12). Mechanical loading is crucial for the health and function 
of the meniscus, as it can drive either anti-inflammatory or 
pro-inflammatory responses as well as influence the balance 
of ECM turnover toward anabolism or catabolism, depend-
ing on magnitude, frequency, and duration, in both humans 
and dogs (12, 13). Mechanisms involved in mechanosensing 
and osmosensing of meniscal fibrochondrocytes are not fully 
understood. Nevertheless, cell substrate-mediated responses, 
mainly driven by calcium, have been identified in  vitro 
(14–16). Meniscal cells also contribute to the joint lubrica-
tion by secreting mucoproteins into the SF (17), produced by 
penetration of a plasma filtrate from vascularized synovial 
membrane. Apart from plasma proteins, SF also contains mol-
ecules secreted by articular chondrocytes and synovial cells, 
including hyaluronan and lubricin, respectively. The function 
of the SF is to facilitate joint movement, absorb mechanical 
loads, and provide transport medium for exchange of gases, 
nutrients, and waste products. Importantly, the SF in injured 
and degenerative joints contains pro-inflammatory cytokines, 
catabolic enzymes, and pain mediators, spreading them to 
non-affected parts of the joint and promoting disease progres-
sion and pain (17).
In both human and dog, approximately 25% of the meniscus 
(outer part) is vascularized, while the inner part receives nutri-
tion by diffusion from the SF (18, 19). Therefore, the outer zone 
has higher capacity to heal spontaneously, while inner meniscus 
has much more limited healing capacity. Healing mechanisms 
in the vascularized zone include cell-mediated tissue repair 
(by stem cells, neutrophils, macrophages, and lymphocytes), 
tissue-remodeling molecules, oxygen, and nutrients. As the 
inner meniscus is not connected to the bloodstream, inner 
meniscal tears have little capacity to heal, typically resulting in 
maceration and degeneration of the affected meniscal tissue (7). 
Innervation of the meniscus coincides with the vascularization 
pattern, as most nerves are associated with vessels. The outer 
one-third of the meniscus and the anterior and posterior horns 
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are innervated by nerves providing proprioceptive and sensory 
function (6). Mechanoreceptors are located at the horns and 
attachment structures, whereas free nerve endings are found 
throughout the meniscus, except for the inner one-third of the 
meniscal body (20).
Pathology
Meniscal lesions represent the most common intra-articular 
knee injury and are the most frequent cause for knee surgery in 
humans (7, 21). The younger population typically suffers from 
traumatic meniscal injuries (e.g., due to sports) with or without 
associated ligament ruptures, while older people are affected by 
degenerative tears that can be symptomatic or asymptomatic (8, 
22). Importantly, meniscal damage is associated with main pain-
ful knee pathologies both in human and dog (6, 23, 24). Common 
human knee pathologies are described below. Although less is 
known about underlying pathophysiological mechanisms on 
canine stifle disorders, these mechanisms are thought to be 
similar.
Aging of the Knee Joint
The prevalence of knee pain increases with age (1). The normal 
aging process is caused by a progressive loss of cell function 
and ability to effectively maintain the ECM. Therefore, age-
related changes in menisci and cartilage of both human and 
dog arise from natural senescence process (25, 26). The effects 
of aging on meniscus in human include loss of collagen fiber 
organization, decreased cell function, and reduced cell density, 
loss of water content, and associated detrimental changes to its 
material properties (25, 27). Anisotropies in the ECM give rise 
to variations in the distribution of local stress and strain and 
alter cell and ECM responses to mechanical loading (27, 28). 
Structural disorganization of the ECM can progress to meniscal 
lesions (29). Physiological loading has beneficial effects on the 
aging meniscus by promoting transport of nutrients through the 
inner avascular part. However, the meniscal repair capacity is 
reduced with age such that even physiological loading can result 
in pathology (26, 30).
Cruciate Ligament Ruptures
Traumatic ligament ruptures are common in athletes and 
physically active people, while ligament degeneration associated 
with OA affects the elderly (31). Ligament ruptures alter joint 
kinematics and cause instability and abnormal loading, contact 
areas, and contact pressures. As a consequence of abnormal knee 
biomechanics, the meniscus is at higher risk for impingement 
and damage. ACL ruptures and meniscal tears eventually result 
in OA (23). It has been suggested that up to 80% of knees with 
an injured ACL demonstrate evidence of OA and meniscal dam-
age at 5–15 years after initial injury (32). Age-related decline in 
ligament structure includes ECM degeneration and shifts in cell 
density and phenotypes both in human and dog (33, 34).
Osteoarthritis
Osteoarthritis, the most prevalent form of skeletal disease, 
represents a leading cause of disability in middle and old age. 
OA affects 40% of people above 70  years of age, being more 
prevalent than any other form of arthritis (35). OA is associated 
with a progressive loss of articular cartilage; however, the details 
of its etiology and pathogenesis remain unclear. OA knees are 
characterized by degenerative destruction of articular cartilage, 
meniscal tears and degeneration, and changes in ligament integ-
rity accompanied by pain. Due to the complex nature of the knee 
joint, OA can be both a consequence and a cause of meniscal 
tears (23). A spontaneous or traumatic meniscal tear can disturb 
knee biomechanics, leading to OA, but knee OA can also cause 
a meniscal tear by abnormal loading and breakdown of menis-
cal structure (22). Meniscal vascular densities are increased in 
human patients with OA. However, the contribution of meniscal 
angiogenesis to symptom progression and joint pathology in OA 
is unclear (36).
Normal aging process and degeneration of menisci can be 
accelerated by several risk factors, such as gene polymorphisms. 
A polymorphic gene consists of an allele that causes abnormal 
gene expression and protein production, influencing the onset 
and severity of associated disorders (37). Several studies identi-
fied gene polymorphisms that can significantly influence the 
pathology of the knee and stifle of humans and dogs, respectively. 
Gene polymorphisms can alter promoter activity, influence tran-
scription factor binding, and may result in shorter transcripts or 
faster product decay. Investigating polymorphisms associated 
with meniscus pathology could provide insight into disease 
mechanisms, reveal therapeutic targets, and help identify patients 
at high risk. However, apart from two studies that reported an 
association of polymorphisms in growth differentiation factor 
5 (GDF5) and CD40 with meniscus injury in Chinese popula-
tion (38, 39), polymorphisms associated with meniscal injury 
are still unknown. Targeting molecular pathways regulated by 
polymorphic genes may become important in the development of 
patient-specific treatments. Other risk factors that contribute to 
the progression of meniscal pathology include systemic inflam-
mation, bacterial infection, overloading (e.g., due to overweight), 
and injury (23, 40, 41).
TRANSLATiONAL MODeLS FOR 
MeNiSCAL PATHOLOGY
Animal models are crucial in facilitating translation of basic 
research findings to practical clinical applications that ultimately 
enhance human health and quality of life. Biological mechanisms 
of meniscal damage and repair have been tested both in small and 
large animal models (7, 42, 43). In general, large animal models 
appear more suitable for meniscal biological studies than small 
animals. Large animals such as sheep or dogs possess a joint 
anatomy and tissue composition close to humans. Their tissue 
characteristics include comparable molecular diffusion distances 
and biomechanical behavior, making large animals more relevant 
for translational therapeutic testing. As an example, sheep have 
meniscal dimensions, vascularization pattern, cellularity, and col-
lagen structure similar to humans (7, 9, 44). However, large animal 
models require higher costs, especially if studies are focused on 
long-term effects of experimental treatments. Small animals such 
as rodents and rabbits can be successfully used for uncovering 
TABLe 1 | Characteristics of experimental canine models for meniscal pathologies.
Model Trigger Meniscal damage Resulting OA Synovial inflammation Reference
Cranial cruciate ligament/anterior cruciate  
ligament transection
Joint instability Secondary Moderate to severe Yes (47, 50)
Meniscal release Joint instability Primary Moderate to severe Yes (51–53)
Meniscectomy Joint instability Removal Related to the size of the preserved 
meniscus
Yes (7, 54)
Cartilage grooving Chondral damage Secondary Mild Yes (47)
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biological mechanisms underlying tissue functions as well as for 
pilot therapeutic studies. However, their distinct anatomy and 
physiology make them less relevant for translational therapeutic 
testing. As an example, rabbit menisci contain significantly more 
cells, more expansive vascularization pattern, and different col-
lagen structure compared with humans (7, 9, 45). Therefore, the 
choice of animal to be used to test a given hypothesis depends on 
several factors including study design, length, budget, outcome 
measures, stage of development, and intended application (46, 
47). Detailed reviews on translational animal models for degen-
erative disorders of the knee are available (4, 46).
To date, most studies aimed at translational meniscal research 
have focused on simulating the effects of partial or total menis-
cectomies in animal models, with the goal of studying the roles of 
the deficient meniscus in the development of OA and methods to 
mitigate associated joint pathology (7). However, results obtained 
from these studies cannot fully assess the effects of degenerative 
or traumatic meniscal tears in the development and progression 
of OA. Animal models where meniscal injury is induced by 
transection of the cranial cruciate ligament (CCL), equivalent to 
ACL, allow for study of mechanical and degenerative meniscal 
pathology associated with instability, but are also limited in clini-
cal applicability based on untreated instability and the inability to 
mimic age-related degenerative changes in the knee.
The most frequently used large animal model for knee patholo-
gies is the dog (47). The canine stifle has similar anatomical 
and physiological characteristics to the human knee (4, 48, 49). 
The canine meniscus has comparable vascularization pattern, 
cellularity, collagen structure, and similar permeability (7, 45). 
However, dog’s menisci differ from human menisci in biome-
chanical properties such as aggregate modulus, shear modulus 
and anatomy, indicating that caution is needed when choosing 
the dog as a model for biomechanical studies (5, 45). Two types of 
canine meniscal pathology can be distinguished: experimentally 
induced and spontaneous.
experimentally induced Meniscal 
Pathology in Dog
Experimentally induced meniscal pathology is created using 
several canine models designed to study meniscal deficiency 
and associated OA, as well as meniscal repair and regeneration 
treatment strategies. In these models, summarized in Table  1, 
meniscal pathology is either surgically created (meniscectomy, 
meniscal release) or indirectly induced with CCL transection. 
As outlined above, each of these models have limitations with 
respect to clinical applicability. For this reason, accurate modeling 
of meniscal degeneration may require study of spontaneously 
occurring meniscal pathology (47).
Spontaneously Occurring Meniscal 
Pathology in Dog
Although experimentally induced pathologies have certain 
advantages, such as reduced disease variability among subjects, 
spontaneous meniscal pathologies in canine patients are highly 
relevant for translational medicine, especially when analyzing 
degenerative processes. Spontaneously occurring meniscal 
pathology can be well studied in dogs, as they are prone to 
CCL disease with concurrent or subsequent meniscal tears 
and secondary OA (6, 49) (Figures  1 and 2). Canine CCL 
ruptures occur most commonly due to a chronic degenerative 
weakening of the ligament causing premature failure and joint 
instability (6, 55, 56). Consequently, femoro-tibial subluxation 
causes shearing forces on the meniscus, which ultimately fails 
presumably adding to pain and joint inflammation. Another 
common type of meniscal pathology in dogs is the degenerative 
tear (57). These tears can present with fraying of the free edge, 
centrally located horizontal tears, fringe tags, interstitial tears, 
radial tears, and/or extensive fibrillation of the meniscus. These 
meniscal lesions are almost invariably accompanied by articular 
cartilage lesions ranging from softening to full-thickness defects 
and associated subchondral bone changes. Both traumatic and 
degenerative meniscal tears are main causes of degenerative 
joint disease in canine patients (17, 23). It has been estimated 
that approximately 20% of dogs older than 1  year of age are 
affected by OA (49). Similarities between canine and human 
patients are not only related to disease progression but also to 
environmental factors (58).
Dogs with spontaneously occurring meniscus disorders are 
useful for studying the roles of meniscus in stifle/knee patholo-
gies and for therapeutic testing. Another important advantage 
of canine patients is the possibility to assess pain via direct 
observation focused on the degree of lameness, gait analysis, 
and subjective rating scales. Subjective rating scales range from 
single visual analog scale assessments to extensive questionnaires 
typically completed by the animal’s owners. The questionnaires, 
comparable to questionnaires used in human clinical trials, 
assess pain through its impact on health-related quality of life. 
Although quality of life and reduction of pain are important 
endpoints in human clinical trials, similar pain scoring systems 
do not exist for other large animal species (59). Apart from the 
scoring systems, biomarkers can be significant diagnostic tools 
to assess progression of the disease and the level of pain. OA 
FiGURe 1 | Meniscal tears in dogs. (A) Grossly normal meniscus with outerbridge grade 1 cartilage pathology; (B) grossly normal meniscus with outerbridge grade 
2 cartilage pathology; (C) displaced bucket handle tear; (D) acute complex tears without gross evidence of degeneration; (e) complex tears with gross evidence of 
degeneration; (F) outerbridge grade 4 of both femoral and tibial articular surface associated with meniscal tear.
FiGURe 2 | (A) A degenerative meniscal tear characterized by fibrillation, softening, and discoloration. (B) An horizontal cleavage tear is apparent when probing the 
mid-substance of the meniscus after performing a partial meniscectomy.
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biomarkers that may possibly differentiate between spontaneous 
CCL disease and other types of OA in canine patients have been 
identified (60).
Furthermore, diagnostic imaging, arthroscopic interven-
tions, and postoperative management similar to human medical 
practice are routinely used in veterinary medicine (4). Depending 
on a study’s design and objectives—especially in the context of 
translation of meniscal therapies—certain similarities and dif-
ferences between human and canine meniscal pathophysiology 
and biological mechanisms underlying progression of meniscal 
degeneration and related pain may be of specific importance and 
will hence be discussed in more detail in the following sections.
BiOLOGiCAL HALLMARKS OF MeNiSCAL 
PATHOLOGY iN HUMAN AND DOG
Progression of knee pathology is a result of both chemical and 
mechanical perturbations arising from complex interactions 
between all tissues of the knee. As one of these tissues, the menis-
cus can have active roles in disease progression and pain. Typical 
biological hallmarks that are seen during progression of knee 
disorders are inflammation, ECM degradation, and oxidative 
damage. Molecules and pathways involved in both age-related 
and trauma-induced damage of the meniscus are illustrated 
below and summarized in Table 2 and Figure 3.
TABLe 2 | Possible therapeutic targets in menisci and SF associated with aging and degenerative knee/stifle disorders.
Therapeutic targets Type of dysregulation Found in human Found in dog
Extracellular matrix (ECM) 
constituents
Glycosaminoglycans Degradation M: unchanged
SF: increased (61)
M: unchanged (62)
SF: fragments (63, 64)
Collagens Degradation M: reduced (27, 65)
SF: increased (66)
M: uk
SF: uk
ECM remodeling ADAMTS4 Overexpression/activity M: yes (67)
SF: (68, 69)
M: uk
SF: uk
ADAMTS5 Overexpression/activity M: uk
SF: (68)
M: uk
SF: uk
MMP1 Overexpression/activity M: yes (67)
SF: yes (70)
M: uk
SF: yes (71)
MMP2 Overexpression/activity M: yes (67)
SF: yes (72)
M: uk
SF: yes (73)
MMP3 Overexpression/activity M: yes (67)
SF: yes (70)
M: uk
SF: yes (63) no (74)
MMP8 Overexpression/activity M: yes (67)
SF: yes (70)
M: uk
SF: uk
MMP9 Overexpression/activity M: yes (75)
SF: yes (72)
M: uk
SF: yes (74)
MMP13 Overexpression/activity M: yes (67)
SF: yes (76)
M: uk
SF: no (74)
Inflammation IL-1α Overexpression/activity M: yes (67)
SF: yes (77)
M: uk
SF: uk
IL-1β Overexpression/activity M: yes (67)
SF: yes (77)
M: uk
SF: yes (63)
IL-6 Overexpression/activity M: yes (67)
SF: yes (77)
M: uk
SF: yes (63, 78)
IL-8 Overexpression/activity M: yes (67)
SF: yes (77)
M: uk
SF: yes (79)
TNF-α Overexpression/activity M: yes (67)
SF: yes (77)
M: uk
SF: yes (63)
14-3-3 Overexpression/activity M: uk
SF: yes (80)
M: uk
SF: yes (81)
Pain Nerve growth factor Increase M: uk
SF: yes (82)
M: uk
SF: yes (83)
Adenosine triphosphate Increase M: uk
SF: (84)
M: uk
SF: yes (85)
Cyclooxygenase-2, prostaglandin E2 Overexpression/activity M: yes (86, 87)
SF: yes (88)
M: uk
SF: (89)
Substance P Increase M: uk
SF: yes (90)
M: uk
SF: uk
Calcitonin gene-related peptide Increase M: yes (91)
SF: yes (92)
M: uk
SF: (58)
Lactic acid Increase M: uk
SF: uk
M: uk
SF: uk
Oxidative stress Advanced glycation end product/receptor for 
advanced glycation end products
Increase overexpression/activity M: yes (87)
SF: yes (93, 94)
M: uk
SF: uk
Reactive oxygen species, NO Increase M: yes (86, 95)
SF: yes (96)
M: uk
SF: yes (82, 97)
M, meniscus; SF, synovial fluid; uk, unknown.
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inflammatory Responses
It has been confirmed that inflammation is a key factor in pro-
gression of many of the human knee disorders leading to OA 
(98). Although articular chondrocytes and cells of the synovial 
membrane are main contributors to the inflammatory and cata-
bolic reactions of the knee, cells of ligaments and menisci also 
FiGURe 3 | Known and putative molecular hallmarks of painful meniscal pathology. Suggested mechanisms in meniscal pathophysiology are inflammation and 
oxidative stress that together contribute to degradation of ECM. IL-1, interleukin-1; TNF-α, tumor necrosis factor alpha; IL1R, interleukin-1 receptor; TNFR, TNF 
receptor; TRAF, TNF receptor-associated factor; IRAK, interleukin receptor-associated kinase; ROS, reactive oxygen species; NO, nitric oxide; SASP, senescence-
associated secretory phenotype; AGEs, advanced glycation end products; PM, plasma membrane; ECM, extracellular matrix.
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overexpress pro-inflammatory and catabolic mediators. In addi-
tion, pro-inflammatory cytokines can be produced by immune 
cells that infiltrate joints due to trauma or age-related cartilage 
degeneration. Severe inflammatory responses in synovium and 
synovial membrane are characteristic for immune-mediated 
disorders (e.g., rheumatoid arthritis), but pro-inflammatory 
cytokines are also active in OA joints (99). In both cases, cytokines 
stimulate cells of neighboring tissues (chondrocytes, ligaments, 
and menisci), contributing to disease progression. The SF plays an 
important role as it spreads inflammatory and catabolic media-
tors within the knee joint.
Interleukin-1 (IL-1α, IL-1β) and tumor necrosis factor alpha 
(TNF-α) are consistently found in degenerative joints. IL-1β and 
TNF-α can stimulate chondrocytes to induce the expression of 
collagenases (MMPs) and aggrecanases (ADAMTSs), promoting 
degradation of the articular tissues’ ECM. At the same time, IL-1β 
and TNF-α activate the expression of other pro-inflammatory 
and pain-generating mediators (100, 101). General mechanisms 
for IL-1β and TNF-α action in chondrocytes is via cell surface 
receptors. Through its receptor IL-1R1, IL-1β can activate 
nuclear factor-κB (NF-κB), p38 mitogen-activated protein 
kinase (MAPK), and/or c-Jun N-terminal protein kinase (JNK). 
The activation of these signaling molecules results in transcrip-
tion and translation of genes for inflammatory cytokines, 
ECM-degrading enzymes, and molecules that promote pain. The 
interaction of TNF-α with its receptor TNFR1 also can activate 
NF-κB and MAPK pathways, through tumor necrosis factor 
receptor-associated factors (67).
Meniscal cells and tissues can be stimulated by pro-inflam-
matory cytokines, providing a good model to study involve-
ment of inflamed meniscus in disease progression as well as 
for therapeutic testing. It has been reported that primary cells 
derived from degenerative human menisci and stimulated with 
pro-inflammatory factors (e.g., IL-1β) exhibit similar inflamma-
tory and catabolic responses as chondrocytes. These cells over-
expressed ECM-degrading enzymes (MMP1, MMP3, MMP13, 
andADAMTS4), cytokines (IL-1α, IL-1β, and IL-6), chemokines 
(IL-8, CXCL1, CXCL2, and CSF1), and components of the NF-κB 
pathway, and underexpressed collagen (67). In human meniscal 
explants, IL-1α and IL-1β impair intrinsic repair capacity by 
increasing expression of MMPs. In addition, MMP inhibitors can 
reduce MMP activity and enhance repair in meniscal explants, 
confirming the importance of MMPs in meniscal homeostasis 
(100, 101). Similar data were obtained in porcine and ovine 
meniscal in vitro models (102). These studies all together suggest 
that meniscal cells are responsive to inflammatory stimulation 
and thus can contribute to progression of knee degeneration and 
pain. However, inflammatory mechanisms in canine meniscus 
have not yet been thoroughly investigated.
Although inflammation-related cell and tissue culture studies 
with canine menisci are rare, the inflammatory profile of the 
painful canine stifle has previously been studied in canine patients 
and animal models. Similar to humans, the SF of dogs with CCL 
transection-induced OA and naturally occurring CCL ruptures 
contains increased levels of IL-1β, IL-6, IL-8, TNF-α, MMP1, 
MMP3, MMP9, C-reactive protein, and 14-3-3-g, compared 
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with healthy SF (58, 63, 78, 79, 81, 103, 104). Although the role 
of 14-3-3 proteins in joint inflammation is not yet established, 
it was shown in humans that these proteins control cell cycle, 
cell growth, differentiation, survival, apoptosis, migration, and 
spreading (80, 105). SF of the canine stifle also contains adenosine 
triphosphate (ATP), with a possible role in pain sensation (85). 
A correlation between the concentration of SF ATP and OA knee 
pain has previously been demonstrated in humans (84), but not 
yet in dogs. Apart from SF, elevated IL-1β, IL-6, and IL-10 were 
found in the synovial membrane of dogs with both OA and CCL 
ruptures (106). In addition, inflammation of SF is associated with 
depletion of proteoglycans from articular cartilage and possibly 
also from menisci. The activity of IL-1β, IL-6, and MMP3 in 
SF of canine stifle joints with naturally acquired CCL ruptures 
correlates with GAG content in the SF, but the source of GAG 
has not been determined (63, 107). Synovium and SF-related 
inflammatory responses in humans do not only occur in OA and 
ligament ruptures but also after meniscal injuries (108). However, 
the association between canine meniscal pathology, SF inflam-
mation, and inflammatory responses of meniscal cells remains 
largely unknown.
Aside from chondrocytes, infiltrating immune cells can be 
another source of inflammation, although their roles in meniscal 
pathology and OA are unclear. Macrophages, T-cells, mast cells, 
B-cells, and plasma cells can be found in human and canine OA 
synovium, where they release inflammatory cytokines into SF 
(109, 110). The synovial membrane and the CCL of dogs with 
CCL ruptures contain significantly increased levels of antibod-
ies to type I and type II collagen, IgG, and IgM, and increased 
expression of intercellular cell adhesion molecule-1 and IL-8, 
when compared with healthy controls (55, 103, 111). Canine 
OA SF contains macrophage-like cells that express significantly 
more collagenolytic enzymes, tartrate-resistant acid phosphatase 
(TRAP), and cathepsin K compared with healthy SF (104). 
Importantly, synovial macrophage-like cells that produce TRAP 
and cathepsin K are significant features of the CCL ruptures 
in dogs, but not in humans, suggesting species-specific differ-
ences in immune responses associated with cruciate ligament 
ruptures (33). Although these findings provide first evidence on 
the involvement of immune cells in inflammation and cartilage 
destruction, exact mechanisms and relative contribution to OA 
remain unknown in both species. Furthermore, acute immune 
reactions are considered beneficial for joint healing. Therefore, 
a complete inhibition of these reactions may not be beneficial.
In addition to the catabolic and pro-inflammatory effects, 
secreted inflammatory cytokines are also involved in the neu-
ronal sensitization and transduction of pain as well as in control-
ling the rate of cell senescence. Human and canine joint disease 
progresses due to the contributing activities of pro-inflammatory 
and catabolic signaling pathways. Nevertheless, significance and 
spatiotemporal expression and activity of individual molecules 
still have to be elucidated.
eCM Changes
Healthy human and canine menisci contain predominantly 
collagen type I produced by fibrochondrocytes (27). Collagen is 
synthesized as pro-collagen and secreted into the ECM, where 
final collagen assembly takes place. Flexible collagen fibers are 
cross-linked by lysyl oxidases to gain additional strength. Under 
physiological conditions, collagen is stable (112). Menisci also 
contain proteoglycans (aggrecan, versican, and perlecan) in lower 
quantities.
Degradation and lamellar disorganization of collagen fibers 
occurs in human aging and contributes to likelihood of meniscal 
tears. Meniscal tears alter the stress distribution in the meniscus, 
increasing the risk for load-induced knee injuries (12). Mechanical 
loads also influence ECM turnover, as non-physiological loading 
of the meniscus can induce synthesis of catabolic and pro-inflam-
matory genes and reduce cell viability (12, 96). On the other hand, 
physiological loading promotes ECM turnover in both articular 
cartilage and menisci. Physiological loading regimes were shown 
to inhibit inflammatory and catabolic responses and activate 
anabolic genes in human articular chondrocytes (28) and induce 
production of collagens and meniscal repair in a canine model 
(13). It was also demonstrated that physical activity modulates 
the synthesis of collagens in the hyaline cartilage of aging dogs, 
partially preserving the cartilage structure (26). Molecular 
mechanisms behind responses to mechanical loading in menis-
cal and articular chondrocytes remain largely unexplored, due to 
the inhomogeneous composition and the anisotropic structure 
of these tissues. Intrinsic coupling of tensile, compressive, and 
shear stresses in  vivo, as well as complex osmolarity and fluid 
flow environments complicate the design of experiments (12). 
Nevertheless, it has been shown that cells in the middle and 
inner human (and ovine) meniscus contain a pericellular region, 
with a possible role in shielding these cells from large mechanical 
strains and stresses. The pericellular region is formed mainly by 
the proteoglycan perlecan that connects cell surface molecules 
with ECM components (113). Interestingly, the perlecan content 
in menisci is reduced with age (114). However, the existence 
and importance of meniscal pericellular region in dogs remains 
unknown.
Collagen can be cleaved enzymatically by collagenases 
(MMPs), whereas proteoglycans are degraded by aggrecanases 
(ADAMTS), expressed by meniscal fibrochondrocytes and other 
cell types such as synovial cells and articular chondrocytes. 
Balanced expression of MMPs and ADAMTS ensures normal 
ECM turnover in a healthy joint. However, the ability of human 
cartilaginous tissues to maintain the ECM declines with age and 
with the degree of degeneration (26, 27, 107). Overexpressed col-
lagenases and aggrecanases are released within the knee joint and 
transported by the SF, enhancing the local catabolic environment. 
Elevated MMPs were also found in the SF of canine patients with 
CCL ruptures and OA (63, 104), but their expression/activity in 
canine menisci was not yet studied. It is likely that an increased 
activity of canine ECM-degrading enzymes, together with age-
related collagen dysfunction and mechanical overloading, can 
reduce exchange of solutes structure, impairing repair capacity 
of the meniscal ECM, and promoting degeneration. Apart from 
collagenases and aggrecanases, human ECM of cartilaginous tis-
sues contains antagonists of inflammatory pathways (e.g., inter-
leukin-1 receptor antagonist), enzyme inhibitors and activators, 
and other molecules diversely affecting cell fate. The importance 
of these molecules in canine menisci remains to be elucidated.
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Cells can sense their local environment via cytoskeleton and 
membrane receptors (115). Ion channels on cell surfaces can be 
activated mechanically, by deformations of the ECM that pull or 
push on these receptors, or chemically, by changes in concentra-
tions and activities of their ligands. Opening ion channels allows 
flux of ions and molecules through these channels, regulating 
various functions, such as cell adhesion, spreading, migration, 
proliferation, and differentiation. As an example, it has been 
shown that fluid flow-induced shear stress causes an increase in 
intracellular Ca2+ and GAG production in isolated rabbit meniscal 
cells (116), but the exact receptors responsible for sensing these 
signals and transporting the Ca2+ into the meniscal cells have yet 
to be identified (12). Candidates could be a family of transient 
receptor potential (TRP) channels that can be activated by vari-
ous mechanical and chemical stimuli. TRP activation is known 
to increase intracellular Ca2+ and induce various cell responses 
(117). For example, TRPV4 activity is important for maintaining 
knee joint health of mice (118), and TRPV5 expression appears 
to be regulated by mechanical loading in articular cartilage of 
rats (119). However, exact mechanisms of channel-mediated 
communication between chondrocytes and their microenviron-
ment are explored neither in human nor in dog. Uncovering the 
role of these receptors in mechanosensing of cartilaginous tissues, 
including meniscus, can improve our understanding of cell–ECM 
communication thus facilitating novel preventative and thera-
peutic strategies for meniscal pathology and the development of 
functional tissue-engineered meniscal implants.
Oxidative Damage
Oxidative damage of macromolecules is mediated by reactive 
oxygen species (ROS), among which superoxide anion radical 
( )O2
− , hydroxyl radical (OH⋅), and nitric oxide (NO) are most 
prominent. ROS formation is a consequence of aerobic metabo-
lism, normal aging processes, and exogenous stress. Cellular 
responses to ROS depend on the ROS concentration and the 
duration of ROS exposure. Although balanced ROS at nanomolar 
concentrations act as signaling molecules in various physiological 
functions, extensive ROS formation damages both cells and ECM 
(120). To ensure a properly maintained redox balance, organisms 
require a complex, coordinated network of antioxidants that 
control ROS production. Cellular and plasma antioxidants, such 
as superoxide dismutase, catalase, and glutathione peroxidase, 
counteract the formation of ROS. However, their activity can 
decrease with age and in degenerated tissues, as shown in human 
(121, 122). Additional radical scavengers, namely vitamins C and 
E, carotenoids, and flavonoids, can be obtained through dietary 
sources, but the delivery of these antioxidants into avascular tis-
sues such as meniscus can be limited (123).
In contrast to many other cell types, the long lifetime of chon-
drocytes and fibrochondrocytes makes them particularly suscepti-
ble to the accumulation of oxidative damage from both aging and 
extrinsic stress (25). As shown in human studies, oxidative damage 
accelerates cell senescence and causes irreversible cell cycle arrest. 
The resulting senescence-associated secretory phenotype is char-
acterized by active release of pro-inflammatory cytokines and an 
altered microenvironment, causing tissue fibrosis and loss of func-
tion (124–126). It has been confirmed that oxidative stress induces 
genomic instability and dysfunction of chondrocytes in human OA 
cartilage explants, suggesting that ROS are involved in the devel-
opment of OA (127). Oxidative stress also activates production of 
nociceptive prostaglandins (PG) and causes time-dependent cell 
death of primary canine CCL cells. As elevated oxidative stress 
markers can be found in damaged human menisci (86, 95), it is 
likely that they also occur in degenerative and damaged canine 
menisci and play active roles in the development of pain. Recently, 
an in vitro study showed that canine chondrocytes are responsive 
to oxidative stress inducer hydrogen peroxide and its detrimental 
effects can be reduced by antioxidants (128). Furthermore, one 
can hypothesize that oxidative stress-induced damage positively 
correlates with degenerative state and/or patient’s age.
Oxidative stress also accelerates accumulation of damaging 
advanced glycation end products (AGEs) both inside and out-
side the cells. AGEs are modified proteins or lipids created by 
non-enzymatic glycation, due to the presence of reducing sugars 
(e.g., glucose). AGEs form irreversible cross-links in long-lived 
proteins of the ECM, preventing their repair and turnover (129). 
Accumulation of AGEs correlates with aging and development of 
knee OA both in humans and dogs (93, 130). In the canine CCL 
transection model, AGEs cause collagen damage and release of 
proteoglycans from CCL, impair its repair capacity, and reduce 
proteoglycan synthesis (131). Apart from the extracellular effects, 
AGEs can increase inflammatory responses of human articular 
and meniscal cells isolated from OA knees, by promoting the 
expression of cyclooxygenase-2 (COX-2) and the release of PG 
E2, MMP1, MMP3, MMP13, and TNF-α (87, 132). Intracellular 
accumulation of AGEs also induces apoptosis of chondrocytes 
via endoplasmic reticulum-related pathways (133). Deleterious 
effects of AGEs on the progression of human OA can be attenu-
ated by inhibition of the receptor for advanced glycation end 
products (RAGE) (132, 134, 135). It has been confirmed that 
RAGE regulates a number of physiological and pathophysiological 
processes and RAGE-dependent signal transduction leads to the 
development of several human diseases (136). As elevated protein 
and mRNA expressions of RAGE were found in SF of human 
patients with knee OA (94), AGE–RAGE signaling appears to be 
a promising therapeutic target (137). No studies on AGE–RAGE 
in degenerative stifles of canine patients are available to assess the 
relevance of this therapeutic target in dogs.
It has been shown that nerve damage and resulting neuropathic 
pain are closely linked with the increased ROS levels (138). 
Degenerated cartilage from human OA patients contains elevated 
oxidative stress markers such as inducible nitric oxide synthase 
(iNOS) and nitrotyrosine, when compared with healthy samples 
(127, 139). Both iNOS and its metabolite NO were shown to inten-
sify the sensation in neuropathic pain (140–142). Overproduction 
of NO was also found in SF isolated from dogs that underwent 
impact injury to the femoral condyle (97). In addition, NO can 
be involved in inflammatory responses that follow CCL damage 
in canine models (143). The importance of oxidative stress con-
tributions to knee and stifle pain have not yet been well defined. 
Nevertheless, it has been shown that the MAP kinase pathways, 
which include ERK, JNK, and p38, can be involved (25, 143, 144). 
Molecules that interfere with oxidative stress, either by radical 
scavenging or by activation of cellular defense mechanisms, can 
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be good therapeutic candidates to prevent ROS-related damage of 
musculoskeletal tissues. In preclinical tests, ROS scavengers were 
shown to reduce PG release and prevent oxidative stress-induced 
death of chondrocytes, suggesting that balancing production of 
ROS in damaged knees can slow down the progression of OA (145).
The Role of the SF
Molecules released within degenerative or damaged knee/stifle 
joint spread through the SF, stimulating nerve endings and activat-
ing pain. In addition, degenerative processes influence hyaluronic 
acid (HA) quantity, quality, and residence time. HA, one of the 
main components of the SF, can be degraded by hyaluronidases, 
especially HYAL2, resulting in reduced joint lubrication, as shown 
in human studies. Expression of HYALs increases in synovium 
of human OA patients, while the expression of HA synthases is 
reduced (146). In addition to reduced joint lubrication, fragmented 
HA can have pro-inflammatory effects (147). Overproduction of 
ROS, e.g., by mechanical overloading, also accelerates HA frag-
mentation and consequently reduces joint lubrication (96, 148). 
Importantly, efficiency of HA-based treatments is decreased by 
ROS produced in damaged knees (149), underscoring the impor-
tance of oxidative stress in knee pathology. Fragmented HA has 
been found in OA knee joints both in human and canine patients 
and is correlated with lower load-bearing capacity (150, 151). It 
is likely that oxidative stress caused by meniscal pathology also 
negatively influences HA in dogs.
CLiNiCAL SiGNiFiCANCe OF MeNiSCAL 
PATHOLOGY
Although a number of dysregulated molecular pathways have 
been implicated in pain both in human knees and canine stifles, 
pain mechanisms associated with damaged menisci are largely 
unknown. Two types of pain can occur: (1) neuropathic pain, 
resulting from neural damage, and (2) nociceptive pain, caused by 
a neural sensitization due to a tissue damage (152). Joint capsule, 
synovium, ligaments, and menisci are innervated by sensory 
nerves, which can be sensitized by various chemicals. Cytokines 
act as nociceptive triggers and also induce the expression of other 
potentially nociceptive molecules and direct pain mediators, such 
as NO and PG E (88). Biosynthesis of PG E2, mediated by COX-2, 
significantly increases in degenerative and injured human tis-
sues, magnifying nociceptive and inflammatory responses (153). 
Neuropeptides such as substance P and nerve growth factor (NGF) 
are located in the sensory nerve endings, and their expression and 
release are associated with OA in humans (82, 154). In addition, 
neuropeptides can be produced by chondrocytes (155). NGF has 
been recognized as an important mediator of chronic pain and as 
a marker of inflammation (156, 157). NGF binds to two differ-
ent receptors on the nociceptor neurons: (1) low-affinity 75-kDa 
neurotrophin receptors (p75NTR), which bind all neurotrophins, 
and (2) tropomyosin-related tyrosin kinase A (TrkA), which 
binds NGF more selectively than the other neurotrophins. NGF-
activated p75NTR regulates a wide range of functions, including 
axonal growth, apoptosis, and myelination (158). NGF signaling 
through TrkA mediates the nociceptive functions of the sensory 
neurons through enhanced expression of substance P, calcitonin 
gene-related peptide, and transient receptor potential vanilloid 1 
(156, 159). Therefore, NGF can be involved in both, pathological 
nerve ingrowth and nerve sensitization in painful human joints. 
As enhanced concentrations of NGF were also found in canine SF 
and correlated with chronic lameness, similar processes are likely 
involved in painful OA of both species (83). However, it is unclear 
whether the damaged meniscus plays an active role in NGF release.
Apart from transmission of pain signals, neuropeptides are 
involved in pathological neo-innervation of degenerative joints. 
By-products of cell metabolism, namely lactic acid, can also be 
noxious through dysregulation of acid sensing ion channels (160). 
Free radicals such as NO are involved in both inflammation and 
nerve damage of human cartilaginous tissues (141, 161). Despite 
the clinical importance of both neuropathic and nociceptive pain, 
mechanisms underlying pain in knee and stifle pathologies are 
not fully understood (3).
Current and prospective treatments for meniscal pathology 
are described in the Data Sheet S1 in Supplementary Material.
CONCLUSiON
Dogs with spontaneously occurring meniscal pathology have the 
potential of being an excellent model for studying mechanisms 
of degeneration and for testing new treatment strategies for both 
dogs and humans. A naturally occurring model of degeneration 
and injury may be appropriate especially for biologic-based and 
tissue engineering approaches, where pre-existing inflammatory 
and catabolic responses largely influence treatment outcomes. 
Although the anatomy, physiology, and pathology of the human 
and canine meniscus are similar, a detailed analysis of the known 
signaling pathways involved in spontaneous meniscus pathology 
in dogs is lacking. Due to lack of knowledge, it is currently not 
possible to fully assess the relevance of dogs with spontaneous 
meniscal pathology as a translational model. To evaluate the 
relevance of this model, more basic research on canine meniscal 
biology and pathophysiology is needed in the future.
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